Severe fever with thrombocytopenia syndrome virus targets B cells in lethal human infections.


Journal

The Journal of clinical investigation
ISSN: 1558-8238
Titre abrégé: J Clin Invest
Pays: United States
ID NLM: 7802877

Informations de publication

Date de publication:
03 02 2020
Historique:
received: 28 03 2019
accepted: 22 10 2019
pubmed: 7 1 2020
medline: 15 9 2020
entrez: 7 1 2020
Statut: ppublish

Résumé

Severe fever with thrombocytopenia syndrome (SFTS) is an emerging hemorrhagic fever caused by a tick-borne banyangvirus and is associated with high fatality. Despite increasing incidence of SFTS and serious public health concerns in East Asia, the pathogenesis of lethal SFTS virus (SFTSV) infection in humans is not fully understood. Numbers of postmortem examinations to determine target cells of the viral infection have so far been limited. Here we showed that B cells differentiating into plasmablasts and macrophages in secondary lymphoid organs were targets for SFTSV at the end stage of lethal infection, and the majority of SFTSV-infected cells were B cell-lineage lymphocytes. In affected individuals, B cell-lineage lymphocytes with SFTSV infection were widely distributed in both lymphoid and nonlymphoid organs, and infiltration of these cells into the capillaries of the organs could be observed occasionally. Moreover, a human plasmablastic lymphoma cell line, PBL-1, was susceptible to SFTSV propagation and had a similar immunophenotype to that of target cells of SFTSV in fatal SFTS. PBL-1 can therefore provide a potential in vitro model for human SFTSV infection. These results extend our understanding of the pathogenesis of human lethal SFTSV infection and can facilitate the development of SFTSV countermeasures.

Identifiants

pubmed: 31904586
pii: 129171
doi: 10.1172/JCI129171
pmc: PMC6994144
doi:
pii:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

799-812

Commentaires et corrections

Type : CommentIn

Références

Virol J. 2018 May 30;15(1):97
pubmed: 29848330
J Med Virol. 1999 Aug;58(4):394-401
pubmed: 10421407
J Virol. 2014 Feb;88(3):1781-6
pubmed: 24257618
PLoS Negl Trop Dis. 2016 Apr 05;10(4):e0004595
pubmed: 27045364
Nat Rev Immunol. 2018 Apr;18(4):255-265
pubmed: 29249807
J Virol. 2018 Sep 12;92(19):
pubmed: 30021900
J Clin Pathol. 2016 Jun;69(6):537-41
pubmed: 26908283
Nat Rev Immunol. 2002 Dec;2(12):920-32
pubmed: 12461565
J Virol Methods. 2017 Jun;244:4-10
pubmed: 28082164
Front Immunol. 2012 Oct 10;3:302
pubmed: 23087687
J Infect Dis. 2014 Mar;209(6):816-27
pubmed: 24231186
BMC Infect Dis. 2018 Oct 22;18(1):528
pubmed: 30348099
Rev Med Virol. 2014 Mar;24(2):90-102
pubmed: 24310908
Emerg Infect Dis. 2013 Nov;19(11):1892-4
pubmed: 24206586
Sci Rep. 2015 Jul 02;5:11816
pubmed: 26134299
N Engl J Med. 2011 Apr 21;364(16):1523-32
pubmed: 21410387
Pathol Int. 2014 Nov;64(11):569-75
pubmed: 25329676
J Pathol. 2006 Aug;209(4):464-73
pubmed: 16741895
Proc Natl Acad Sci U S A. 2012 Jun 19;109(25):10053-8
pubmed: 22665769
Nat Commun. 2018 Aug 20;9(1):3328
pubmed: 30127439
Lancet Infect Dis. 2014 Aug;14(8):763-772
pubmed: 24837566
J Infect Dis. 2012 Oct 1;206(7):1095-102
pubmed: 22850122
Front Immunol. 2012 Apr 17;3:78
pubmed: 22566959
Proc Natl Acad Sci U S A. 2015 Apr 14;112(15):4719-24
pubmed: 25775592
Exp Hematol. 1994 Mar;22(3):261-6
pubmed: 8112425
Lancet Infect Dis. 2018 Oct;18(10):1127-1137
pubmed: 30054190
Cell Immunol. 1999 Oct 10;197(1):1-9
pubmed: 10555990
J Infect Dis. 2015 Sep 15;212(6):889-98
pubmed: 25762790
J Virol. 2012 Aug;86(16):8388-401
pubmed: 22623799
MMWR Morb Mortal Wkly Rep. 2014 Feb 14;63(6):121-6
pubmed: 24522095
J Immunol. 2006 Nov 15;177(10):6930-9
pubmed: 17082608
Annu Rev Pathol. 2013 Jan 24;8:411-40
pubmed: 23121052
PLoS One. 2013 Nov 13;8(11):e80802
pubmed: 24236203
J Clin Virol. 2018 Apr;101:57-62
pubmed: 29427908
Front Microbiol. 2017 Jan 30;8:104
pubmed: 28194148
J Immunol. 2013 Jan 1;190(1):80-7
pubmed: 23203929
Emerg Infect Dis. 2014 Aug;20(8):1358-61
pubmed: 25061851
Sci Rep. 2017 Aug 31;7(1):10188
pubmed: 28860565
EBioMedicine. 2016 Oct;12:178-188
pubmed: 27628668
Cell Host Microbe. 2014 Jul 9;16(1):115-27
pubmed: 24981333
Nat Microbiol. 2019 Mar;4(3):438-446
pubmed: 30531978
J Infect Dis. 2012 Oct 1;206(7):1085-94
pubmed: 22904342
Intern Med. 2016;55(7):831-8
pubmed: 27041174
mSphere. 2016 Jan 06;1(1):null
pubmed: 27303697
J Infect Dis. 2019 Jun 5;220(1):23-27
pubmed: 30721983
N Engl J Med. 2012 Aug 30;367(9):834-41
pubmed: 22931317
Sci Transl Med. 2018 Sep 19;10(459):
pubmed: 30232226
Emerg Infect Dis. 2015 Oct;21(10):1704-10
pubmed: 26402575
J Virol. 2018 Jun 13;92(13):
pubmed: 29643242
Nat Med. 1996 Mar;2(3):342-6
pubmed: 8612236
Korean J Intern Med. 2019 Jul;34(4):902-909
pubmed: 29117665
Clin Infect Dis. 2012 Feb 15;54(4):527-33
pubmed: 22144540
J Infect Chemother. 2018 Apr;24(4):292-297
pubmed: 29138019
J Virol. 2016 May 12;90(11):5292-5301
pubmed: 26984731
J Clin Oncol. 2007 Jul 20;25(21):3168-73
pubmed: 17577023
J Pathol. 2015 Jan;235(2):153-74
pubmed: 25297522
J Infect Chemother. 2018 Oct;24(10):773-781
pubmed: 30098914
EMBO Mol Med. 2018 Mar;10(3):
pubmed: 29363490
PLoS One. 2018 Oct 26;13(10):e0206416
pubmed: 30365543

Auteurs

Tadaki Suzuki (T)

Department of Pathology, National Institute of Infectious Diseases, Shinjuku, Tokyo, Japan.

Yuko Sato (Y)

Department of Pathology, National Institute of Infectious Diseases, Shinjuku, Tokyo, Japan.

Kaori Sano (K)

Department of Pathology, National Institute of Infectious Diseases, Shinjuku, Tokyo, Japan.
Division of Infectious Diseases Pathology, Department of Global Infectious Diseases, Tohoku Graduate School of Medicine, Sendai, Miyagi, Japan.

Takeshi Arashiro (T)

Department of Pathology, National Institute of Infectious Diseases, Shinjuku, Tokyo, Japan.

Harutaka Katano (H)

Department of Pathology, National Institute of Infectious Diseases, Shinjuku, Tokyo, Japan.

Noriko Nakajima (N)

Department of Pathology, National Institute of Infectious Diseases, Shinjuku, Tokyo, Japan.

Masayuki Shimojima (M)

Department of Virology I, National Institute of Infectious Diseases, Musashimurayama, Tokyo, Japan.

Michiyo Kataoka (M)

Department of Pathology, National Institute of Infectious Diseases, Shinjuku, Tokyo, Japan.

Kenta Takahashi (K)

Department of Pathology, National Institute of Infectious Diseases, Shinjuku, Tokyo, Japan.

Yuji Wada (Y)

Department of Pathology, National Institute of Infectious Diseases, Shinjuku, Tokyo, Japan.

Shigeru Morikawa (S)

Department of Veterinary Science, National Institute of Infectious Diseases, Shinjuku, Tokyo, Japan.

Shuetsu Fukushi (S)

Department of Virology I, National Institute of Infectious Diseases, Musashimurayama, Tokyo, Japan.

Tomoki Yoshikawa (T)

Department of Virology I, National Institute of Infectious Diseases, Musashimurayama, Tokyo, Japan.

Masayuki Saijo (M)

Department of Virology I, National Institute of Infectious Diseases, Musashimurayama, Tokyo, Japan.

Hideki Hasegawa (H)

Department of Pathology, National Institute of Infectious Diseases, Shinjuku, Tokyo, Japan.
Division of Infectious Diseases Pathology, Department of Global Infectious Diseases, Tohoku Graduate School of Medicine, Sendai, Miyagi, Japan.
Global Virus Network, Baltimore, Maryland, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH